Arginine butyrate-induced susceptibility to ganciclovir in an Epstein- Barr-virus-associated lymphoma

Blood Cells, Molecules and Diseases

Volumn 24, Issue 2, 1998, Pages 114-123

  Mentzer, Steven J ^a,b   Fingeroth, Joyce ^a   Reilly, John J ^a   Perrine, Susan P ^a   Faller, Douglas V ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Antiviral; Immunosuppression; Lung transplantation; Lymphoproliferative disease; Post transplant; Thymidine kinase

Indexed keywords

GANCICLOVIR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER RISK; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; VIRUS CARCINOGENESIS;

EID: 0032104738     PISSN: 10799796     EISSN: None     Source Type: Journal    
DOI: 10.1006/bcmd.1998.0178     Document Type: Article

References (58)

1. 1. Armes JE, Angus P, Southey MC, et al. Lymphoproliferative disease of donor origin arising in patients after orthotopic liver transplantation. Cancer 74: 2436-2441, 1994.
2. 2. Cohen JI. Epstein-Barr virus lympho-proliferative disease associated with acquired immunodeficiency. Medicine (Baltimore) 70:137-160, 1991.
3. 3. Schwend M, Tiemann M, Kreipe HH, et al. Rapidly growing Epstein-Barr virus-associated pulmonary lymphoma after heart transplantation. Eur Respir J 7:612-616, 1994.
4. 4. Hanto DW, Frizzera G, Gajl-Peczalska KJ, et al. Epstein-Barr virus-induced B-cell lymphoma after renal transplantation: acyclovir therapy and transition from polyclonal to monoclonal B-cell proliferation. N Engl J Med 306:913-918, 1982.
5. 5. Breinig MK, Zitelli B, Starzl TE, Ho M. Epstein-Barr virus, cytomegalovirus, and other viral infections in children after liver transplantation. J Infect Dis 156:273-279, 1987.
6. 6. Ross CW, Schnitzer B, Sheldon S, et al. Gamma/ delta T-cell posttransplantation lymphoproliferative disorder primarily in the spleen. Am J Clin Pathol 102:310-315, 1994.
7. 7. Kawashima K, Hayashi K, Ohnoshi T, et al. Epstein-Barr virus-associated post-transplant non-Hodgkin's lymphoma: establishment and characterization of a new cell line. Jpn J Cancer Res 85:1080-1086, 1994.
8. 8. Rooney CM, Loftin SK, Brenner MK, et al. Early detection and treatment of EBV-associated post transplant lymphoproliferative disease. XVIII Intl-.Herpesvirus Workshop Abstract B-37, 1993.
9. 9. Kuo PC, Dafoe DC, Alfrey EJ, et al. Posttransplant lymphoproliferative disorders and Epstein-Barr virus prophylaxis. Transplantation 59:135-138, 1995.
10. 10. Egan JJ, Hasleton PS, Yonan N, et al. Necrotic, ulcerative bronchitis, the presenting feature of lymphoproliferative disease following heart-lung transplantation. Thorax 50:205-207, 1995.
11. 11. Purtilo DT, Sakamoto K, Barnabei V, et al. Epstein-Barr virus-induced diseases in boys with the X-linked lymphoproliferative syndrome (XLP): update on studies of the registry. Am J Med 73:49-56, 1982.
12. 12. List AF, Greco FA, Vogler LB. Lymphoproliferative diseases in immunocompromised hosts: the role of Epstein-Barr virus. J Clin Oncol 5:1673-1689, 1987.
13. 13. Kaplan MA, Ferry JA, Harris NL, et al. Clonal analysis of posttransplant lymphoproliferative disorders, using both episomal Epstein-Barr virus and immunoglobulin genes as markers. Am J Clin Pathol 101:590-596, 1994.
14. 14. Henle W, Henle G. Epstein-Barr virus and human malignancies. Adv Viral Oncol 5:201-238, 1985.
15. 15. Gulley ML, Raphael M, Lutz CT, et al. Epstein-Barr virus integration in human lymphomas and lymphoid cell lines. Cancer 70:185-191, 1992.
16. 16. Sabourin JC, Kanavaros P, Briere J, et al. Epstein-Barr virus (EBV) genomes and EBV-encoded latent membrane protein (LMP) in pulmonary lymphomas occurring in nonimmunocompromised patients. Am J Surg Pathol 17:995-1002, 1993.
17. 17. Cen H, Williams PA, McWilliams HP, et al. Evidence for restricted Epstein-Barr virus latent gene expression and anti-EBNA antibody response in solid organ transplant recipients with posttransplant lymphoproliferative disorders. Blood 81:1393-1403, 1993.
18. 18. Ho M, Jaffe R, Miller G, et al. The frequency of Epstein-Barr virus infection and associated lymphoproliferative syndrome after transplantation and its manifestations in children. Transplantation 45:719-727, 1988.
19. 19. Tao Q, Srivastava G, Loke SL, et al. Epstein-Barr virus (EBV)-related lymphoproliferative disorder with subsequent EBV-negative T-cell lymphoma. Int J Cancer 58:33-39, 1994.
20. 20. Riddler SA, Breinig MC, McKnight JL. Increased levels of circulating Epstein-Barr virus (EBV)-infected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of posttransplant lymphoproliferative disease in solid-organ transplant recipients. Blood 84:972-984, 1994.
21. 21. Joseph G, Barker RL, Yuan B, et al. Posttransplantation plasma cell dyscrasias. Cancer 74: 1959-1964, 1994.
22. 22. Delecluse HJ, Rouault JP, French M, et al. Posttransplant lymphoproliferative disorders with genetic abnormalities commonly found in malignant tumours. Br J Haematol 89:90-97, 1995.
23. 23. Frank D, Cesarman E, Liu YF, et al. Posttransplantation lymphoproliferative disorders frequently contain type A and not type B Epstein-Barr virus. Blood 85:1396-1403, 1995.
24. 24. Levine AM. Lymphoma complicating immunodeficiency disorders. Ann Oncol 5 Suppl 2:29-35, 1994.
25. 25. Schubach WH, Hackman R, Neiman PE, et al. A monoclonal immunoblastic sarcoma in donor cells bearing Epstein-Barr virus genomes following allogeneic marrow grafting for acute lymphoblastic leukemia. Blood 60:180-187, 1982.
26. 26. Littler E, Zeuthen J, McBride AA, et al. Identification of an Epstein-Barr virus-coded thymidine kinase. EMBO J 5:1959-1966, 1986.
27. 27. Stinchcombe T, Clough W. Epstein-Barr virus induces a unique pyrimidine deoxynucleoside kinase activity in superinfected and virus-producer B cell lines. Biochemistry 24:2027-2033, 1985.
28. 28. Lin JC, Smith MC, Pagano JS. Prolonged inhibitory effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine against replication of Epstein-Barr virus. J Virol 50:50-55, 1984.
29. 29. Littler E, Arrand JR. Characterization of the Epstein-Barr virus-encoded thymidine kinase expressed in heterologous eucaryotic and procaryotic systems. J Virol 62:3892-3895, 1988.
30. 30. Newman C, Polk BF. Resolution of oral hairy leukoplakia during therapy with 9-(1,3-dihydroxy-2-propoxymethyl)guanine (DHPG). Ann Intern Med 107:348-350, 1987.
31. 31. Resnick L, Herbst JS, Ablashi DV, et al. Regression of oral hairy leukoplakia after orally administered acyclovir therapy. JAMA 259:384-388, 1988.
32. 32. Contreras-Salazar B, Ehlin-Henriksson B, Klein G, et al. Up regulation of the Epstein-Barr virus (EBV)-encoded membrane protein LMP in the Burkitt's lymphoma line Daudi after exposure to n-butyrate and after EBV superinfection. J Virol 64:5441-5447, 1990.
33. 33. Ito Y, Kawanishi M, Harayama T, et al. Combined effect of the extracts from Croton tiglium, Euphorbia lathyris or Euphorbia tirucalli and n-butyrate on Epstein-Barr virus expression in human lymphoblastoid P3HR-1 and Raji cells. Cancer Lett 12:175-180, 1981.
34. 34. Roubal J, Luka J, Klein G. Effect of retinoic acid (RA) on the Epstein-Barr virus (EBV)-inducing effect of sodium butyrate. Cancer Lett 8:209-212, 1980.
35. 35. Saemundsen AK, Kallin B, Klein G. Effect of n-butyrate on cellular and viral DNA synthesis in cells latently infected with Epstein-Barr virus. Virology 107:557-561, 1980.
36. 36. Anisimova E, Prachova K, Roubal J, et al. Effects of n-butyrate and phorbol ester (TPA) on induction of Epstein-Barr virus antigens and cell differentiation. Arch Virol 81:223-237, 1984.
37. 37. Mentzer SJ, Longtine J, Fingeroth J, et al. Immunoblastic lymphoma of donor origin in the allograft after lung transplantation. Transplantation 61: 1720-5, 1996.
38. 38. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanatephenol-chloroform extraction. Anal Biochem 162: 156-159, 1987.
39. 39. Weng H, Choi SY, Faller DV The Moloney leukemia retroviral long terminal repeat trans-activates AP-1-inducible genes and AP-1 transcription factor binding. J Biol Chem 270:13637-13644, 1995.
40. 40. Feinberg AP, Vogelstein B. A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Anal Biochem 132:6-13, 1983.
41. 41. Mundschau LJ, Forman LW, Weng H, et al. Platelet-derived growth factor (PDGF) induction of egr-1 is independent of PDGF receptor autopho-sphorylation on tyrosine. J Biol Chem 269:16137-16142, 1994.
42. 42. Ginis I, Faller DV. Quantitative estimation of the degree of cell spreading on different surfaces and cell monolayers using a fluorescent plate scanner. Anal Biochem 219:288-296, 1994.
43. 43. Sanders DA, Tansan ST, Arthur V, et al. Phase I clinical trial of arginine butyrate in patients with refractory neoplasms. Proc Am Soc Clin Oncol 14:476, 1995.
44. 44. Faller DV, Perrine SP. Butyrate in the treatment of sickle cell disease and beta-thalassemia. Curr Opin Hemat 2:109-117, 1995.
45. 45. Perrine SP, Ginder GD, Faller DV, et al. A short-term trial of butyrate to stimulate fetal-globin-gene expression in the beta-globin disorders. N Engl J Med 328:81-86, 1993.
46. 46. Perrine SP, Faller DV Butyrate-induced reactivation of the fetal globin genes: a molecular treatment for the beta-hemoglobinopathies. Experientia 49: 133-150, 1993.
47. 47. Perrine SP, Miller BA, Faller DV, et al. Sodium butyrate enhances fetal globin gene expression in erythroid progenitors of patients with Hb SS and beta thalassemia. Blood 74:454-459, 1989.
48. 48. Papadopoulos EB, Ladanyi M, Emanuel D, et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation [see comments]. N Engl J Med 330:1185-1191, 1994.
49. 49. Armitage JM, Kormos RL, Stuart RS, et al. Posttransplant lymphoproliferative disease in thoracic organ transplant patients: ten years of cyclosporine-based immunosuppression. J Heart Lung Transplant. 10:877-86; discussion 886-7, 1991.
50. 50. Bieber CP, Heberling RL, Jamieson SW, et al. Lymphoma in cardiac transplant recipients associated with cyclosporin A, prednisone and antithymocyte globulin (ATG). in Immune Deficiency and Cancer, Purlito DT ed, New York: Plenum, 1984.
51. 51. Nalesnik MA, Jaffe R, Starzl TE, et al. The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am J Pathol 133:173-192, 1988
52. 52. Oettle H, Wilborn F, Schmidt CA, et al. Treatment with ganciclovir and Ig for acute Epstein-Barr virus infection after allogeneic bone marrow transplantation [letter]. Blood 82:2257-2258, 1993.
53. 53. Fingeroth JD. Epstein-Barr virus associated proliferative disease and neoplasia. Inf Dis Prac 13:1-13, 1990.
54. 54. Hanto DW, Birkenbach M, Frizzera G, et al. Confirmation of the heterogeneity of posttransplant Epstein-Barr virus-associated B cell proliferations by immimoglobulin gene rearrangement analyses. Transplantation 47:458-464, 1989.
55. 55. Ho M, Miller G, Atchison RW, et al. Epstein-Barr virus infections and DNA hybridization studies in posttransplantation lymphoma and lymphoproliferative lesions: the role of primary infection. J Infect Dis 152:876-886, 1985.
56. 56. Cen H, Breinig MC, Atchison RW, et al. Epstein-Barr virus transmission via the donor organs in solid organ transplantation: polymerase chain reaction and restriction fragment length polymorphism analysis of IR2, IR3, and IR4. J Virol 65:976-980, 1991.
57. 57. Novogrodsky A, Dvir A, Ravid A, et al. Effect of polar organic compounds on leukemic cells. Butyrate-induced partial remission of acute myelogenous leukemia in a child. Cancer 51:9-14, 1983.
58. 58. Miller AA, Kurschel E, Osieka R, et al. Clinical pharmacology of sodium butyrate in patients with acute leukemia. Eur J Cancer Clin Oncol 23:1283-1287, 1987.